A senescent cell can be likened to a worker who refuses to retire: it ceases to perform its function, remains within the tissue, and persistently releases chemical signals that induce stress in neighboring cells. This analogy illustrates the disruptive role of senescent cells within the body.
Cellular senescence refers to the permanent cessation of cell division, typically triggered by damage or excessive stress. While this process serves as a protective mechanism, since non-dividing cells cannot become cancerous, senescent cells are not immediately removed. Instead, they persist and secrete a range of inflammatory factors collectively termed the Senescence-Associated Secretory Phenotype (SASP). The accumulation of senescent cells with age leads to chronic low-grade inflammation, which contributes to the development of conditions such as arthritis, heart disease, and Alzheimer’s disease.
A major challenge in the field has been the lack of a single, reliable assay to identify senescent cells. Researchers must rely on a combination of biomarkers, such as the enzyme SA-β-galactosidase and the protein p16, to approximate the presence of senescence. This multi-marker approach complicates the identification process.
A recent study published in Aging Cell (2025) by researchers at Mayo Clinic proposes a potential solution to this longstanding problem.
What Are DNA Aptamers And Why Do They Matter?
Aptamers are short, single-stranded DNA (or RNA) molecules that fold into precise three-dimensional shapes, allowing them to bind to specific targets with remarkable accuracy, much like antibodies, but made entirely of genetic material. They’re cheaper to produce, easier to modify, and small enough to penetrate tissues that larger proteins can’t reach.
The research team, led by L. James Maher III and colleagues, used a powerful selection technique called SELEX (Systematic Evolution of Ligands by Exponential Enrichment) to identify aptamers that specifically bind to senescent cells.
Rather than targeting a predetermined molecule on senescent cells, the researchers began with a library of approximately 100 trillion random DNA sequences and allowed biological selection to determine specificity. This pool of DNA molecules was exposed to senescent mouse fibroblast cells (positive target) and non-senescent cells (negative control). Only DNA strands that bound to senescent cells, but not to healthy cells, were retained and amplified. This selection process was repeated over nine rounds, progressively enriching for the most effective aptamers.
By the seventh round, the selected library demonstrated a marked increase in binding affinity for senescent cells compared to healthy cells, indicating successful enrichment of specific aptamers.
The Results: Aptamers That Recognize Zombie Cells
From the final pool, ten candidate aptamer sequences were isolated and evaluated. Nearly all demonstrated significantly stronger binding to senescent cells than to healthy counterparts. This specificity was consistent across various senescence induction methods, including DNA-damaging agents, X-ray irradiation, and hydrogen peroxide exposure.
Importantly, the aptamers also exhibited efficacy across multiple cell types, including muscle cells (C2C12 myoblasts) and liver cells (AML12 hepatocytes), as well as the fibroblasts used for selection. This cross-cell-type performance suggests that the aptamers recognize a general feature of senescence rather than a cell line-specific characteristic.
One notable limitation is that the selected aptamers did not bind to senescent human cells, indicating specificity for mouse cells. Although this restricts immediate clinical application, the researchers attribute this to species-level differences in the molecular target and propose that a similar selection process could be conducted using human cells in future studies.
The Target: A Sneaky Form of Fibronectin
Using a sophisticated proteomics technique called SILAC (Stable Isotope Labeling by Amino Acids in Cell Culture), the team identified the specific molecule the aptamers were binding to. The answer? Fibronectin, specifically a splice variant called FN-EDA (Fibronectin containing Extra Domain A).
Fibronectin is a large protein found in the extracellular matrix, the scaffolding that surrounds and supports cells. But not all fibronectin is the same. The FN-EDA isoform is a variant that appears to be more abundant in tissues with a higher senescence burden. Previous research had already hinted at an association between FN-EDA and aging-related conditions, including atherosclerosis and lung fibrosis.
What’s particularly interesting is that the aptamers bound fibronectin with extraordinary precision; the binding affinities measured were 921 picomolar (for aptamer 6756) and 579 picomolar (for aptamer 6762). To put that in perspective, picomolar binding is considered exceptionally strong; it means the aptamer binds its target tightly even at vanishingly low concentrations.
Even more telling: conventional anti-fibronectin antibodies did not show the same staining pattern as the aptamers. This suggests that the aptamers recognize a distinct senescence-specific form of fibronectin, something that traditional tools have missed entirely.
Aging Mice Tell the Story In Vivo
The team didn’t stop at cell cultures. They tested aptamer 6762, one of the strongest performers, on lung tissue sections from mice aged 3, 6, 12, 18, 22, and 30 months.
The results indicated that aptamer staining was minimal in young mice, while a substantial increase was observed in mice aged 22 and 30 months, corresponding to advanced age. This finding aligns with the established understanding that senescent cells accumulate progressively with aging.
To confirm the association between aptamer staining and senescent cells, the researchers utilized the INK-ATTAC transgenic mouse model, in which p16-expressing senescent cells can be selectively eliminated by administration of AP20187. Following treatment and removal of senescent cells in aged mice, aptamer staining in lung tissue decreased significantly, whereas conventional fibronectin antibody staining remained unchanged. This result supports the conclusion that the aptamers detect a senescence-specific feature rather than general fibronectin.
Why This Could Be a Big Deal
This research has several important implications for the field.
Better diagnostics. Right now, identifying senescent cells in tissue samples requires multiple staining steps and expert interpretation. A single aptamer probe that reliably flags senescent cells would dramatically simplify this process and would be useful in both research settings and, eventually, clinical diagnostics.
Enhanced senolytic therapies: Senolytics are drugs intended to selectively eliminate senescent cells. While agents such as dasatinib and quercetin have demonstrated potential, their lack of specificity remains a limitation. Conjugating a senolytic payload with an aptamer that targets senescent cells could improve delivery precision and minimize adverse effects on healthy tissue.
A new framework for aging research. By using an unbiased selection approach rather than searching for known targets, this study opens the door to discovering entirely new senescence biology. The aptamers may be flagging molecular changes we didn’t even know were happening.
What Comes Next
The researchers are clear that this is a proof-of-concept study, a demonstration that this approach works, not a ready-to-use clinical test. Several important steps remain:
- Running similar SELEX selections with human senescent cells to develop aptamers relevant to human aging.
- Improving selection robustness by incorporating multiple cell types and senescence-induction methods across different rounds.
- Understanding exactly which structural or chemical feature of FN-EDA the aptamers recognize could reveal new biology of the senescent extracellular matrix.
For a field that has sought a universal senescence marker for decades, DNA aptamers represent a novel and promising direction for future research.
The Takeaway
It is well established that senescent cells, often referred to as ‘zombie cells,’ are significant contributors to aging and age-related diseases. However, precise and reliable tools for their identification have been lacking. This research demonstrates that unbiased DNA aptamer selection can yield molecular probes with high specificity for senescent cells, highlighting a previously unrecognized fibronectin variant as a potential senescence marker.
Although this represents early-stage research and significant work remains before clinical translation, the approach demonstrates the potential to leverage natural selection to identify highly effective molecular probes. This underscores the value of harnessing biological mechanisms in scientific discovery.
References
Pearson, K.S., Jachim, S.K., Doherty, C.D., Wilbanks, B.A., Prieto, L.I., Dugan, M., Baker, D.J., LeBrasseur, N.K., & Maher, L.J. III. (2025). An unbiased cell-culture selection yields DNA aptamers as novel senescent cell-specific reagents. Aging Cell, 24, e70245. https://doi.org/10.1111/acel.70245